LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 6, 2014--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that Anne
Whitaker will join the Company as President, Chief Executive Officer and
a member of the Company’s Board of Directors effective September 2,
2014. Ms. Whitaker has more than 20 years of experience in the
pharmaceutical industry, principally at GlaxoSmithKline and Sanofi
including, most recently, the role of President, North America
Pharmaceuticals, at Sanofi.
Anne Whitaker, President and Chief Executive Officer, Synta Pharmaceuticals
(Photo: Business Wire)
“It is with great pleasure that the Board welcomes Anne Whitaker as
Synta’s new Chief Executive Officer,” said Keith Gollust, Chairman of
the Board of Synta. “Anne brings a wealth of experience to Synta, gained
over a distinguished career in executive roles with two of the world’s
top pharmaceutical companies. Her knowledge and experience in business
strategy, product development, regulatory affairs, leadership and
organizational development and commercialization will be invaluable to
the Company as we continue to advance ganetespib through late stage
development.”
“Synta presents an exciting opportunity defined by a late stage product,
ganetespib, that has shown promising activity in multiple indications
and a pre-clinical program, HDC, that has significant potential to
generate new drug candidates.” said Ms. Whitaker. “I am excited to join
the very talented and dedicated team at Synta at this important time in
the Company’s evolution. I look forward to working with this team to
build a world-class global oncology and immunology business that
delivers improved health to patients, innovative treatment solutions to
healthcare providers and value to shareholders.”
As President, North America Pharmaceuticals, at Sanofi, Ms. Whitaker
oversaw all pharmaceutical and consumer healthcare operations within the
region, including the Diabetes, Oncology, Cardiovascular and other
Patient Centered Units, Chattem (CHC), U.S. Market Access, U.S. Medical
and Regulatory Affairs, Business Strategy, Planning & Operations and
Canada Pharmaceuticals. She also served as a member of Sanofi’s Global
Leadership Team, Global Commercial Operations Committee and U.S.
Regional Management Committee.
A distinguished and dedicated professional with more than 20 years of
experience, Anne began her career at Delta Communications and joined the
Upjohn Company in 1991 as a metabolic disease specialist. She joined
GlaxoSmithKline in 1992 as a sales representative and held various
leadership positions in the Commercial organization. In 2001, she became
Vice President of Critical and Supportive Care before being appointed
Senior Vice President of Leadership and Organization Development from
2008 to 2009. In 2009, Anne became Senior Vice President and Business
Unit Head, Cardiovascular, Metabolic and Urology (CVMU) at
GlaxoSmithKline, where she had full commercial responsibility for
leading, developing and managing strategic performance of the CVMU
business. In September 2011, she joined Sanofi as President, North
America Pharmaceuticals.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using its compound
library and discovery capabilities. For more information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified
by the use of forward-looking terminology such as "will", "would",
"should", "expects", "anticipates", "intends", "plans", "believes",
"may", "estimates", "predicts", “continues”, "projects", or similar
expressions intended to identify forward-looking statements. Such
statements, including statements relating to the advancement of
ganetespib through late stage development, activity of ganetespib in
multiple indications and the potential for HDC to generate additional
drug candidates, reflect Synta’s current views with respect to future
events and are based on assumptions and subject to risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements, including
those described in "Risk Factors" of our Form 10-K for the year ended
December 31, 2013 as filed with the Securities and Exchange Commission.
Synta undertakes no obligation to publicly update forward-looking
statements, whether because of new information, future events or
otherwise, except as required by law.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140806005388/en/
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Daniel Cole, 781-541-7250
[email protected]
or
Argot
Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Media:
Argot
Partners
Eliza Schleifstein, 917-763-8106
[email protected]